The best biopharma M&A deals
Listen now
Description
At Fierce Biotech, we love a big M&A deal, but valuation does not always equal the most exciting.   In this week's episode of "The Top Line," Fierce Biotech’s Annalee Armstrong and James Waldron discuss what they think are the best and smartest acquisitions in recent years.   From obesity to radiopharmaceuticals, they give you the Fierce Biotech team’s thoughts on who got the best deal.  To learn more about the topics in this episode:   Top 10 smartest deals in biopharma  See omnystudio.com/listener for privacy information.
More Episodes
Every year, Fierce’s pharma, biotech, and medtech teams come together to spotlight some of the fiercest women in life sciences—leaders who are transforming the industry with their innovation and impact. This year, our special report celebrates 10 women driving change in clinical research,...
Published 11/22/24
Published 11/22/24
 Last month, the NIH announced that it had found evidence of research misconduct by Eliezer Masliah, M.D., the head of the neuroscience division at the National Institute on Aging. The NIH announcement coincided with the Sept. 26 publication of an investigation by Science, finding that 132 papers...
Published 11/15/24